QC
DERM icon

Quadrature Capital’s Journey Medical DERM Stock Holding History

Quadrature Capital’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,181
Closed -$94.4K – 1135
2025
Q2 		$94.4K Buy
+13,181
New +$91.1K ﹤0.01% 898

Other funds holding DERM

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Quadrature Capital's DERM Position: Q3 2025 in Review

Quadrature Capital sold out of Journey Medical (DERM) in Q3 2025, closing a stake of 13,181 shares — an estimated $94.4K sold.

Quadrature Capital first reported a position in DERM in Q2 2025 and held it in 1 quarter. The position peaked at $94.4K in Q2 2025. 68 funds tracked by Wall St. Rank hold DERM as of Q3 2025.

  • Quadrature Capital reported no remaining Journey Medical position as of Q3 2025 after selling out during the quarter.
  • Quadrature Capital sold 13,181 Journey Medical shares in Q3 2025, an estimated $94.4K.
  • Quadrature Capital first reported a position in Journey Medical in Q2 2025 and held it in 1 quarter.
  • Quadrature Capital's Journey Medical position peaked at $94.4K in Q2 2025.
  • 68 funds tracked by Wall St. Rank held Journey Medical as of Q3 2025.

Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.